IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran

03. Dezember 19:02 Dow Jones: Es hört nicht auf...

03. Dezember 19:50 Commerzbank und Deutsche Bank: "Bitte keine großzügige ...

03. Dezember 20:20 Apple unter Druck – aber die Lage hellt sich langsam auf

03. Dezember 21:33 Schlussglocke: Dow Jones schließt schwache Woche mit weiterem Minus ab

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021